TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02208466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham repetitive transcranial magnetic stimulation (rTMS)
Description: Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham repetitive transcranial magnetic stimulation (rTMS)
Description: Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Fluoxetine
Description: Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
Study: NCT00792467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
Study: NCT00609934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiotherapy
Description: 3000cGy in 10 fractions
Study: NCT01391026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced patient-centered care
Description: The experimental arm will be referred to a multi-disciplinary clinic
Study: NCT04187612

Intervention type: DEVICE
Intervention: Bioelectrical Impedance Analysis (BIA)
Description: BIA will be used to determine total body water
Study: NCT02450656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study: NCT04325126

Intervention type: OTHER
Intervention: Exposure factors
Description: Exposure factors，such as diet，exercise，environment

Intervention type: OTHER
Intervention: Exposure factors
Description: Exposure factors，such as diet，exercise，environment

Intervention type: OTHER
Intervention: Exposure factors
Description: Exposure factors，such as diet，exercise，environment

Intervention type: OTHER
Intervention: Exposure factors
Description: Exposure factors，such as diet，exercise，environment

Intervention type: OTHER
Intervention: Exposure factors
Description: Exposure factors，such as diet，exercise，environment
Study: NCT03852901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin (Jardiance) 25 mg
Description: Oral empagliflozin 25 mg/day x 14 days
Study: NCT01731951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Description: Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Description: Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Description: Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Description: Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Description: Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Description: Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.
Study: NCT02079077

Intervention type: DRUG
Group type: OTHER
Intervention: Acetylsalicylic Acid (ASA)
Description: Acetylsalicylic Acid (ASA) 81 mg. oral daily for two months

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine (HCQ)
Description: Hydroxychloroquine (HCQ) 200 mg. oral, daily for two months.
Study: NCT04246918

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched Chain Amino Acid
Description: Branched chain amino acid is a group of three amino acids known for there role in muscle growth.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whey Protein concentrate powder
Description: Whey protein will be given to the standard treatment arm including in the same amount of 1.5gm/kg/IBW.
Study: NCT01631123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isocaloric high carbohydrate diet intervention
Description: Time of 6 week, the last 6 days are standardized

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isocaloric high fat diet intervention
Description: Time of 6 weeks; the first and the last 6 days are standardized
Study: NCT00658918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide nasal
Description: safety of Ciclesonide (200µg, 100µg, 25µg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide nasal
Description: safety of Ciclesonide (200µg, 100µg, 25µg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide nasal
Description: safety of Ciclesonide (200µg, 100µg, 25µg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01404546

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
Study: NCT04279210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: The RegenKit-THT (RegenLab SA, Switzerland) was used to separation of plasma and blood cells. 3mL PRP was extracted from the bottom of the plasma. PRP was injected into anterior vaginal wall, near external urethral sphincter, and into endopelvic fascia.
Study: NCT00610129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0646
Description: MK-0646 (20 mg/mL) in sterilized solution for IV infusion (12.7 mL to deliver 12.0 mL) will be used for a dose of 10 mg/kg IV weekly administered over 60 minutes.
Study: NCT00634699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active Comparator, ischemic compressions
Description: Ischemic Compressions,3 times a week,5 weeks.
Study: NCT03884985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual stimulation
Description: In the experiments, participants will sit in front of a computer monitor located a less than a meter of distance and will analyze the content of images extracted from collections of natural and computer-generated scenes. Subjects will be asked to report verbally or by pressing keys on a keyboard on image characteristics such as the locations of the objects present in the scenes, their number and/or their identities. Some experiments will involve a search paradigm in which subjects will have to report on the location and/or fine characteristics of a target element among a field of distracting similar elements, and/or visual discrimination tasks. The duration of the interval of time in which the image is maintained on the screen may be varied between few tens of milliseconds to several seconds. In a set of experiments, the eye movements performed by the subjects during the execution of the visual tasks will be recorded as explained below.
Study: NCT05115175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Participants engaged in meditation and self-led exercises to help them understand and cope with stress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Participants engaged in meditation and self-led exercises to help them understand and cope with stress.
Study: NCT00710268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV administration10 mg/kg every 14 days
Study: NCT02470481

Intervention type: OTHER
Intervention: No Intervention
Description: This is an obervational study
Study: NCT00349869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: 8-week yoga program.
Study: NCT00945815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epratuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT01803958

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole breast irradiation
Study: NCT00816816

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel, cisplatin, fluorouracil
Description: neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly.
Study: NCT02646878

Intervention type: DEVICE
Group type: OTHER
Intervention: Harmony 1 Sensor
Description: Use of Harmony 1 Sensor for 10 days when inserted in the arm and abdomen and used with the Guardian Mobile in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 6 months.

Intervention type: DEVICE
Group type: OTHER
Intervention: Harmony 1 Sensor
Description: Use of Harmony 1 Sensor for 10 days when inserted in the arm and abdomen and used with the Guardian Mobile in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 6 months.
Study: NCT01956396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex™ device
Description: PrePex™ device for adult male circumcision. The non-surgical PrePex™ device with No Injected Anesthesia
Study: NCT04462159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction Program
Description: Education, exercise, teaching kitchen and nutrition, and psychological support
Study: NCT04442932

Intervention type: DEVICE
Intervention: Blood Collection
Description: K3-EDTA venous whole blood 9 mL 1 venous draw
Study: NCT03696342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazufloxacin
Description: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.
Study: NCT02791906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISMN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISMN

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Study: NCT01784172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture group
Description: Procedure: electro-acupuncture;Points: Bilateral Zhongliao (BL33) Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50～60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with continuous wave,50 Hz and electric current 1- 5mA.Every session lasts for 30 min per day.The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham electroacupuncture group
Description: Procedure: sham electroacupuncture;Points: Bilateral sham Zhongliao (BL33) sham Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Both sham BL33 and BL35 are given non-penetrating needling with blunt needle. Twirl, lift and thrust for 3 times. The sham electric stimulator is applied to bilateral sham BL33 and sham BL35. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
Study: NCT03048175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wisdom tooth removal
Description: After inferior dental and buccal nerve anesthesia a triangular full thickness flap with releasing incision on the mesio-buccal aspect of the second molar is designed. Ostectomy is then performed and tooth is sectioned and gently elevated. Once all the tooth components are extracted, the socket is carefully inspected and flap is sutured with interrupted sutures.
Study: NCT02210026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seattle-PAP
Description: We propose to test the hypothesis that by introduction of variation in airway pressure Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) reduces work of breathing in very low birth weight infants more effectively than standard bubble nasal continuous positive airway pressure.
Study: NCT01428570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pentax-AWS (AWS; Pentax Corporation, Tokyo, Japan)
Description: Each group of patients will be intubated using the Macintosh laryngoscope or Pentax-AWS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pentax-AWS (AWS; Pentax Corporation, Tokyo, Japan)
Description: Each group of patients will be intubated using the Macintosh laryngoscope or Pentax-AWS.
Study: NCT04162717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Effect of Telephone Symptom Triage Protocols on Symptom Management, Quality of Life and Self-Care Maintenance in Patients with Cancer Who Applied Systemic Treatment
Description: Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later.~Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles.
Study: NCT04227665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sea level
Description: Sea level exposure / sea level exposure combined with microdoses of rHuEPO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude
Description: Altitude exposure / altitude exposure Iron metabolism
Study: NCT04422145

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured nurse led intervention programme
Description: A diabetes research nurse, over a period of 12 months, provided a structured education programme to participants focussing on the avoidance of hypoglycaemia and the treatment of this if/when it occurred.
Study: NCT03646929

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MEP using standard facilitation technique
Description: measuring of MEP using standard facilitation technique according to the Guidelines of International Federation of Clinical Neurophysiology

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MEP using standard facilitation technique
Description: measuring of MEP using standard facilitation technique according to the Guidelines of International Federation of Clinical Neurophysiology

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MEP using modified facilitation technique
Description: measuring of MEP using modified facilitation technique (application of additional 8-12x magnetic stimuli for arms and legs)
Study: NCT04429347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Friday night: 1 capsule of 300 mg, Saturday night: 2 capsule of 300 mg (total 600 mg), Sunday night: choice of 1 or 2 capsule of 300 mg (total of 300 or 600 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Friday night: 1 capsule, Saturday night: 2 capsule, Sunday night: choice of 1 or 2 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Description: Friday night: 1 capsule of 2 mg, Saturday night: 2 capsule of 2 mg (total 4 mg), Sunday night: choice of 1 or 2 capsules of 2 mg (total of 2 or 4 mg)
Study: NCT04422145

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Participants continue on their current diabetes care plan and are looked after by their usual diabetes care provider
Study: NCT02586493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive 1 inhalation once-daily until visit 2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
Study: NCT03696342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zymar
Description: Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.
Study: NCT00878904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Study: NCT03249779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scrambler
Description: Scrambler Therapy is a specific form of electrical stimulation which has also been utilized in chronic neurogenic pain11. This modality of therapy differs from TENS in that the goal is to mediate the patient's perception of pain, rather than masking the peripheral pain signal. The results of this modality of treatment may be longer-lasting than TENS, presumably via reduction in central signal generation. Scrambler therapy works through C fibers to retrain the peripheral sensation in the area being treated. Further description of this technology is available at: International Patent PCT/IT2007/000647 and U.S. Patent No. 8,380,317. Literature search does not yield prior studies regarding efficacy of Scrambler therapy in treating RLS
Study: NCT02416427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin will be administered at 80 mg/day for 3 weeks in the time window between diagnostic biopsy and curative surgery
Study: NCT03601429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactogyn
Description: capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules
Study: NCT00646737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium
Description: Mycophenolate sodium
Study: NCT01503528

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motor Sparing Nerve Block
Description: Continuous Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peri-articular Catheters
Description: 3 peri-articular catheters inserted at the end of surgery followed by periarticular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices.
Study: NCT01452308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simtuzumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Study: NCT01998048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Latarjet
Description: A diagnostic arthroscopy is performed before the Latarjet operation in general anaesthesia. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeons' decision by inserting 1 to 2 more suture anchors according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect. Thereafter an open Latarjet operation is performed using standard techniques described by Walch or de Beer. A deltopectoral incision is used. The coracoid process is osteotomized and ventrally prepared to bleeding bone. The coracoid process is then transferred through the middle of the subscapularis and re-attached on to the freshened neck of the glenoid, just medial to the joint line with two screws and washers, according to the surgeon's preference.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bankart
Description: An arthroscopic Bankart operation is performed in general anaesthesia according to current practise (Provencher 2010). The intra-articular findings are recorded and the anteroinferior labrum and the IGHL are mobilized until subscapular muscle fibers can be seen. The IGHL complex is then re-attached to the freshened neck of the glenoid with 2 to 3 suture anchors according to surgeon's preference to re-create labral bumper and capsular tension. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeon's decision by inserting 1 to 2 more suture anchors, according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect.
Study: NCT02357069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel
Description: Etanercept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBEC0101
Description: Etanercept